The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Updated use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine.
Thomas H. Cartwright
Consultant or Advisory Role - Amgen; Genentech; Lilly; Sanofi
Honoraria - Amgen; Lilly; Roche; Sanofi
Aimee Ginsburg Arlen
No relevant relationships to disclose
Lalan S. Wilfong
No relevant relationships to disclose
Robyn K. Harrell
No relevant relationships to disclose
J. Russell Hoverman
Employment or Leadership Position - US Oncology/McKesson Specialty Health
Roy A. Beveridge
Employment or Leadership Position - US Oncology/McKesson Specialty Health